JW THERAP-B (02126): Carteyva (relma-cel injection) included in the National Basic Medical Insurance Drug Catalog
JW THERAP-B (02126) announced that the company's core product Carteyva (relma-cel injection) has been officially included in the 2026 version of the National Reimbursement Drug List (NRDL). Starting from January 1, 2027, patients who fall within the national medical insurance payment scope can receive basic medical insurance reimbursement for Carteyva as stipulated. This medical insurance payment scope covers all three approved indications of Carteyva, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Carteyva upon inclusion in the National Reimbursement Drug List is RMB288,600.
JW THERAP-B (02126) announced that the company's core product Carteyva (relma-cel injection) has been officially included in the 2026 National Reimbursement Drug List (NRDL). Starting from January 1, 2027, patients who fall within the national medical insurance payment scope will be eligible for basic medical insurance reimbursement when using Carteyva in accordance with regulations. This medical insurance payment scope covers all three approved indications of Carteyva, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Carteyva included in the National Reimbursement Drug List is RMB288,600.
As the only chimeric antigen receptor T-cell (CAR-T) therapy product included in the National Reimbursement Drug List this time, Carteyva will further lower the payment threshold for eligible patients to receive CAR-T treatment, helping this cutting-edge innovative therapy benefit more patients. With further improvement in payment coverage, CAR-T treatment is expected to be more widely incorporated into clinical diagnosis and treatment decisions, promoting timely identification, referral, and assessment of patients who may benefit. Clinicians can comprehensively evaluate treatment options and timing of intervention based on patients' disease progression, prior treatment history, and individualized needs, to formulate more reasonable treatment plans for eligible patients.
Related Articles

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.
GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.






